DexCom Inc.
Dexcom
Dexcom is the global leader in continuous glucose monitoring (CGM) technology, founded in 1999 in San Diego, California, USA. With annual revenue of $4.66 billion, the company operates 4+ manufacturing facilities including new sites in Ireland and Arizona, serving over 100 countries. Dexcom's CGM systems have revolutionized diabetes management by eliminating fingerstick blood tests for millions of patients worldwide.
Strengths: 100% pure-play CGM focus with $4.66B revenue growing 16% YoY; FDA-approved 15-day wear G7 sensor with industry-leading MARD accuracy; seamless integration with insulin pumps for automatedclosed-loop systems; strong cash position with $9.1B GAAP operating profit at 19.6% margin.
Weaknesses: Single-product category risk (CGM only); intense competition from Abbott and Medtronic in CGM space; dependency on US market for majority of revenue.Read More ▼Show Less ▲
Strengths: 100% pure-play CGM focus with $4.66B revenue growing 16% YoY; FDA-approved 15-day wear G7 sensor with industry-leading MARD accuracy; seamless integration with insulin pumps for automatedclosed-loop systems; strong cash position with $9.1B GAAP operating profit at 19.6% margin.
Weaknesses: Single-product category risk (CGM only); intense competition from Abbott and Medtronic in CGM space; dependency on US market for majority of revenue.
Listed market data
DXCM · NASDAQ · weeklyHistory →- Market cap
- $32.5 B
- Share price
- USD 86.04
- 1Y change
- +29.2%
- Recent change
- -0.5%
- IPO price
- ×25.8
- Revenue (TTM)
- $5 B
10-22 → 10-23
USD 12.00 · from 4/14/2005
Financial history
Full market history- 2026-10USD 86.04$32.5 B-0.3%
- 2026-09USD 86.29$35.9 B-5.2%
- 2026-08USD 91.06$37.9 B+9.1%
- 2026-07USD 83.45$34.8 B+23.9%
- 2026-06USD 67.35$28 B-8.7%
- 2026-05USD 73.74$30.7 B+23.8%
- 2026-04USD 59.55$24.8 B-5.2%
- 2026-03USD 62.80$26.2 B-14.5%
- 2026-02USD 73.43$30.6 B+0.5%
- 2026-01USD 73.04$30.4 B+10.0%
- 2025-12USD 66.37$27.6 B+4.6%
- 2025-11USD 63.47$26.4 B—
In the press
All coverage →5 latest headlines1- DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - TradingViewwww.tradingview.com2026-10-20
- The Dexcom G7 is Proof That Your CGM Should Do More Than Tell You What Has Already Happened - Women Love Techwomenlovetech.com2026-10-19
- Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actionstopclassactions.com2026-10-18
- DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives - Seeking Alphaseekingalpha.com2026-10-18
- Dexcom faces a class action over an alleged data breach that ShinyHunters claimed responsibility for. - Claim Depotwww.claimdepot.com2026-10-16
• Dexcom G7 CGM system with 15-day wear time and industry-leading MARD accuracy
• G7 sensor, transmitter, and receiver product line for home diabetes management
• Smart Basal automated insulin delivery integration with major insulin pumps
• Stelo over-the-counter glucose biosensor for non-diabetic health monitoring
• Dexcom CLARITY clinic software for healthcare provider data review
• Real-time glucose data sharing via smartphone app for caregivers
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $4.7 B | $836 M |
| 2024 | $4 B | $576 M |
| 2023 | $3.6 B | $542 M |
| 2022 | $2.9 B | $341 M |
| 2021 | $2.4 B | $217 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
San Diego, California, United States
Founded
1999
Employees
9000+
Revenue
$4.7 B
Market cap
$32.5 B
Factories
4+ factories in 3 countries
Listing
NASDAQ: DXCM
Categories
Related
Similar listed companies
- Nvidia Corporation· $5.2 T
- Eli Lilly and Company· $1.1 T
- Micron Technology, Inc.· $994 B
- ASML Holding N.V.· $631 B
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NASDAQ: DXCM , Data Sources & Methodology
Dexcom Official Website
Dexcom FY2025 Results
Dexcom - Wikipedia
Dexcom Global Careers & Facilities